through a wide range of group-centered packages and pursuits. In fiscal 12 months 2021, Penn Drugs presented more than $619 million to advantage our community.
Approach of Study
Randomized controlled/scientific trial
Topic of Investigation
Engineered neuronal microtissue delivers exogenous axons for delayed nerve fusion and rapid neuromuscular restoration in rats
Write-up Publication Date
Editor’s Note: Dr. Cullen is a co-founder of Axonova Clinical, LLC, and Innervace, Inc., which are the two College of Pennsylvania (Penn) spinout organizations focused on the translation of superior regenerative therapies to take care of nervous program diseases. Dr. Cullen’s laboratory at Penn gets sponsored analysis funding from Axonova Health care. Penn and Dr. Cullen just about every personal fairness interests in the two businesses, have been given license-relevant fiscal consideration and might receive additional economical thought in the future connected to the licensing of specified Penn intellectual property to these organizations.
Disclaimer: AAAS and EurekAlert! are not accountable for the precision of news releases posted to EurekAlert! by contributing institutions or for the use of any facts by way of the EurekAlert process.